Purchase Order HHSN261201300309P

The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded a $1,903,737.98 definitive cost-no-fee contract to Brigham & Women's Hospital in Boston, Massachusetts. The contract is for a Phase II clinical trial of celecoxib for the prevention of sporadic colorectal adenomas, with Dr. Monica Bertagnolli serving as the Principal Investigator and Dr. Asad Umar as the Contracting Officer's Technical Representative. The contract does...

The University of Texas M.D. Anderson Cancer Center has been awarded a $912,585 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ vehicle to repurpose the macrolide antibiotic clarithromycin for the prevention of lung and breast cancer. The work will be performed under the PREVENT Program's PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS major program code, with the goal of assessing clarithromycin's preclinical efficacy and...

The National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a $536,992.49 delivery order contract to Mayo Clinic to conduct a pilot study on the use of the EGFR inhibitor erlotinib to inhibit fibrogenesis and prevent hepatocellular carcinoma in patients with cirrhosis. This contract is part of NCI's Cancer Prevention Agent Development Program, which supports early-phase clinical research. Mayo Clinic is a non-profit academic medical center that frequently provides research...

This federal contract award, valued at $999,843.18, was issued by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) for a randomized phase II clinical trial evaluating the effects of low-dose aspirin versus placebo in high-risk individuals with CT screen-detected lung nodules. The contract is part of NCI's Cancer Prevention Agent Development Program and supports early-phase clinical research. MD Anderson has collaborated with several...

This federal contract award, with an ID of HHSN261201200035I|HHSN26100007, was made by the National Cancer Institute (NCI) to Northwestern University to conduct a clinical trial studying the effects of simvastatin on reducing the risk of recurrent pancreatitis. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early-phase clinical research. The $1,114,905.38 contract does not have a set-aside designation. The clinical trial will randomize 30 patients...

This federal contract was awarded by the National Cancer Institute, a component of the National Institutes of Health, to Mayo Clinic. The $853,948.77 contract is for a Phase II clinical trial to evaluate weekly dosing of the drug erlotinib to reduce duodenal polyp burden in patients with familial adenomatous polyposis. The contract does not have a set-aside designation. Mayo Clinic has collaborated with the University of Utah, University of Michigan, and University of Puerto Rico as...

This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the Cancer Hospital, Chinese Academy Of Medical Sciences. The contract, which is a definitive contract with a firm fixed price, is for "UPPER GASTROINTESTINAL CANCER PREVENTION STUDIES" and has a period of performance from September 20, 2017 to September 19, 2018. The potential value of the contract is $398,291.00, and the completion date...

This federal contract award, issued by the National Cancer Institute, is for a Phase I single-arm, multicenter pilot study to validate Y-OHPDG as a biomarker and test the effects of Polyphenon E on its levels in patients with cirrhosis. The $1,410,682.11 contract was awarded to Northwestern University, which will serve as the prime contractor. Georgetown University and the University of Puerto Rico Medical Sciences Campus are listed as subcontractors. The contract is part of the National...

This is a delivery order issued under the National Cancer Institute's PREVENT Cancer Program (PREVENT) contract. The order, valued at $834,263.00, was awarded to the University of Oklahoma Health Sciences Center (OUHSC) to determine the potential clinical usefulness of aspirin and naproxen (another NSAID) for prostate cancer prevention using preclinical models. The University of Colorado-Denver is a subcontractor supporting this research. The award has a period of performance from July 2016 to...

The National Cancer Institute awarded The Institute For Cancer Research a firm fixed-price delivery order valued at $1.24M under the PREVENT Preclinical Drug Development Program, with performance scheduled to conclude on November 17, 2026. This task order, titled "Next Generation GP130/IL-6/STAT3 Inhibitors for the Prevention of Colitis-Associated Colorectal Cancer," was awarded on May 18, 2022, without set-aside designation. The Institute For Cancer Research, a non-profit subsidiary...